5LH0.F Guard Therapeutics International AB (publ)
- Market cap
- EUR 3.07M
- P/E
- -
- P/B
- 0.68x
- ROE
- -69.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is 5LH0.F undervalued?
Graham numberThe Graham number of Guard Therapeutics International AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guard Therapeutics International AB (publ) fundamental analysis
No fundamental analysis for Guard Therapeutics International AB (publ) yet.
Guard Therapeutics International AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guard Therapeutics International AB (publ)
Disruptive Pharma AB (publ) operates as a pharmaceutical technology company in Sweden. The company develops and commercializes Formulite, a patented and clinically evaluated platform technology for oral drug formulation and drug product development. The company is based in Stockholm, Sweden.
Full company profileGuard Therapeutics International AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guard Therapeutics International AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -81.3M | -114M | -115M | -100M | -108M | -26.1M |
| EBITDA | - | -113M | -113M | -96.1M | -109M | -25.4M |
| Net Income | -82.0M | -113M | -113M | -96.1M | -109M | -25.4M |
| EPS | -11 | -11 | -11 | -7.49 | -5.40 | -1.26 |
| Balance Sheet | ||||||
| Total Assets | 190M | 203M | 85.2M | 55.7M | 54.1M | 45.0M |
| Total Liabilities | 14.7M | 25.2M | 18.5M | 17.8M | 13.5M | 8.46M |
| Shareholders' Equity | 176M | 177M | 66.7M | 38.0M | 40.6M | 36.5M |
| Cash & Short-term Investments | 189M | 201M | 83.7M | 54.2M | 49.8M | 41.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -77.6M | -102M | -116M | -94.8M | -109M | -35.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -77.6M | -102M | -116M | -94.8M | -109M | -35.6M |
| Ratios | ||||||
| ROE | -46.7% | -63.6% | -169.8% | -253.0% | -267.9% | -69.5% |
| ROA | -43.1% | -55.7% | -133.0% | -172.3% | -201.0% | -56.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Guard Therapeutics International AB (publ) dividends
Guard Therapeutics International AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:50 on Dec 15, 2023.
Who owns Guard Therapeutics International AB (publ)
- Insiders 13.01%
- Institutions 19.22%
- Public & others 67.77%
- Shares outstanding 44.6M
- Free float 15.9M
Guard Therapeutics International AB (publ) company profile
- Company name
- Guard Therapeutics International AB (publ)
- Ticker
- 5LH0.F
- ISIN
- SE0021181559
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 12
- Fiscal year end
- December
- Address
- Box 5216, Stockholm, Sweden, 102 45
- Phone
- 46 86 70 65 51
- Website
- disruptivepharma.com
About Guard Therapeutics International AB (publ)
Disruptive Pharma AB (publ) operates as a pharmaceutical technology company in Sweden. The company develops and commercializes Formulite, a patented and clinically evaluated platform technology for oral drug formulation and drug product development. The company is based in Stockholm, Sweden.
Guard Therapeutics International AB (publ) management
2- Mr. Peter Åsberg Ph.D.Chief Executive Officer
- Ms. Karin BothaChief Financial Officer · born 1973